Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Infectious Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.
- Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis.Lancet Infect Dis. 2018; 18: 318-327
- Review on Antimicrobial Resistance Tackling drug-resistant infections globally: Final report and recommendations. AMR Review website.(Available at:https://amrreview.org/#:∼:text=%E2%80%9CThe%20Review%20on%20Antimicrobial%20Resistance,actions%20to%20tackle%20it%20internationally)(Accessed 2022 July 13)Date: 2016
- WHO Publishes List of Bacteria for Which New Antibiotics are Urgently Needed.(Available from) ([Last accessed on 2022 July 13)
- Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data.Open Forum Infect Dis. 2019; 6: ofz344
- Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae.Antimicrob Agents Chemother. 2019; 63: e01733-19
- Pharmacoepidemiology of ceftazidime-avibactam use: a retrospective cohort anlaysis of 210 US hospitals.Clin Infect Dis. 2020; 72: 611-621
- Buying Time: The AMR Action Fund and the State of Antibiotic Development in the United States 2020.Open Forum Infect Dis. 2020; 7: ofaa464
- Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum beta-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).Clin Infect Dis. 2021; 72: e169-e183
- Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase producing Enterobacterales, Carbapenem-resistant Acinetobacter baumainnii, and Stenotrophomas maltophilia infections.Clin Infect Dis. 2022; 74: 2089-2114
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine).Clin Microbiol Infect. 2022; 28: 521-547
- IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections.Clin Microbiol Infect. 2022; 28: 465-469
- New Perspectives on Antimicrobial Agents: Cefiderocol.Antimicrob Agents Chemother. 2021; 65: e0217120
- In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria.Antimicrob Agents Chemother. 2018; 62: e01454-17
- Antibacterial Resistance Leadership G. A Primer on AmpC beta-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.Clin Infect Dis. 2019; 69: 1446-1455
- Induction of beta-lactamases.J Antimicrob Chemother. 1988; 22: 37-44
- Molecular basis of beta-lactamase induction in bacteria.Antimicrob Agents Chemother. 1993; 37: 153-158
- The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms.Clin Infect Dis. 1995; 21: 1107-1113
- Regulatory components in Citrobacter freundii ampC beta-lactamase induction.Proc Natl Acad Sci U S A. 1985; 82: 4620-4624
- Citrobacter koseri and Citrobacter amalonaticus isolates carry highly divergent beta-lactamase genes despite having high levels of biochemical similarity and 16S rRNA sequence homology.J Antimicrob Chemother. 2004; 53: 1076-1080
- Novel class A beta-lactamase Sed-1 from Citrobacter sedlakii: genetic diversity of beta-lactamases within the Citrobacter genus.Antimicrob Agents Chemother. 2001; 45: 2287-2298
- Characterization of indole-positive Proteus mirabilis.Appl Microbiol. 1972; 23: 592-594
- Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent beta-Lactam-beta-Lactamase Inhibitor Combination.Antimicrob Agents Chemother. 2019; 63: e00105-e00119
- Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.Biochemistry. 2010; 49: 1014-1023
- New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world.Antimicrob Agents Chemother. 2014; 58: 1835-1846
- Interplay between beta-lactamases and new beta-lactamase inhibitors.Nat Rev Microbiol. 2019; 17: 295-306
- Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?.Int J Antimicrob Agents. 2013; 41: 236-249
- The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae.Clin Infect Dis. 2013; 57: 781-788
- Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use.Antimicrob Agents Chemother. 2008; 52: 995-1000
- Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy.Ann Intern Med. 1991; 115: 585-590
- Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp.Antimicrob Agents Chemother. 2001; 45: 2628-2630
- Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC beta-lactamase.J Antimicrob Chemother. 2018; 73: 1530-1536
- Three Yersinia enterocolitica AmpD Homologs Participate in the Multi-Step Regulation of Chromosomal Cephalosporinase, AmpC.Front Microbiol. 2016; 7: 1282
- Nucleotide sequence of the ampC-ampR region from the chromosome of Yersinia enterocolitica.Antimicrob Agents Chemother. 1992; 36: 1049-1052
- Heterogeneity of AmpC cephalosporinases of Hafnia alvei clinical isolates expressing inducible or constitutive ceftazidime resistance phenotypes.Antimicrob Agents Chemother. 2000; 44: 3220-3223
- The Use of Noncarbapenem beta-Lactams for the Treatment of Extended-Spectrum beta-Lactamase Infections.Clin Infect Dis. 2017; 64: 972-980
- Antibacterial in vitro activity of fourth generation cephalosporins.J Chemother. 1996; 8: 31-36
- In vitro selective concentrations of cefepime and ceftazidime for AmpC beta-lactamase hyperproducer Enterobacter cloacae variants.Clin Microbiol Infect. 1999; 5: S25-S28
- Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.J Antimicrob Chemother. 2016; 71: 296-306
- Penicillin-binding proteins and induction of AmpC beta-lactamase.Antimicrob Agents Chemother. 1997; 41: 2013-2015
- Diverse potential of beta-lactamase inhibitors to induce class I enzymes.Antimicrob Agents Chemother. 1990; 34: 156-158
- Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases.Antimicrob Agents Chemother. 2001; 45: 2831-2837
- Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia.Clin Infect Dis. 2014; 58: 1554-1563
- Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.Int J Antimicrob Agents. 2020; 55: 105860
- Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate.Antimicrob Agents Chemother. 2004; 48: 1040-1042
- Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia.J Clin Microbiol. 2005; 43: 4891-4894
- Rapid emergence of resistance to cefepime during treatment.Clin Infect Dis. 1997; 25: 339-340
- Prevalence of outer membrane porin alteration in beta-lactam-antibiotic-resistant Enterobacter aerogenes.Antimicrob Agents Chemother. 1996; 40: 2854-2858
- Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.Antimicrob Agents Chemother. 1996; 40: 1289-1293
Procter and Gamble Pharmaceuticals, Inc. MACROBID - nitrofurantoin monohydrate and nitrofurantoin, macrocrystalline capsule [package insert]. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2009/020064s019lbl.pdf. Accessed October 24, 2022.
- MONUROL (fosfomycin tromethamine) SACHET [package insert].(Available at:) (Accessed 5 August 2020)
- Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial.JAMA. 2018; 319: 1781-1789
- Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.J Antimicrob Chemother. 2006; 58: 256-265
- A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis.Am J Med. 2017; 130: 842-845
- Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017.N Engl J Med. 2020; 382: 1309-1319
- Unreliable extended-spectrum beta-lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates.J Clin Microbiol. 2009; 47: 358-361
Clinical and Laboratory Standards Institute. M100: performance standards for antimicrobial susceptibility testing. 31st edition. Wayne (PA): Clinical and Laboratory Standards Institute; 2021.
- PRO: Testing for ESBL production is necessary for ceftriaxone-non-susceptible Enterobacterales: perfect should not be the enemy of progress.JAC Antimicrob Resist. 2021; 3: dlab019
- Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales.JAC Antimicrob Resist. 2021; 3: dlab020
- Molecular Epidemiology of Ceftriaxone Non-Susceptible Enterobacterales Isolates in an Academic Medical Center in the United States.Open Forum Infect Dis. 2019; 6: ofz353
- Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.Clin Infect Dis. 2017; 65: 110-120
- Prevalence of bla CTX-M Genes in Gram-Negative Bloodstream Isolates across 66 Hospitals in the United States.J Clin Microbiol. 2021; 59: e00127-21
- Epidemiology of beta-Lactamase-Producing Pathogens.Clin Microbiol Rev. 2020; 33: e00047-e19
- Updated functional classification of beta-lactamases.Antimicrob Agents Chemother. 2010; 54: 969-976
- Contemporary diversity of beta-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent beta-lactamase groups.Antimicrob Agents Chemother. 2014; 58: 833-838
- Extended-spectrum beta-lactamases: an update on their characteristics, epidemiology and detection.JAC Antimicrob Resist. 2021; 3: dlab092
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.JAMA. 2018; 320: 984-994
- Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study.Clin Infect Dis. 2020; 73: e3842-e3850
- Comparable outcomes for beta-lactam/beta-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.Antimicrob Resist Infect Control. 2015; 4: 14
- Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?.J Antimicrob Chemother. 2012; 67: 1569-1577
- Comparison of five commonly used automated susceptibility testing methods for accuracy in the China Antimicrobial Resistance Surveillance System (CARSS) hospitals.Infect Drug Resist. 2018; 11: 1347-1358
- Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia.Curr Opin Infect Dis. 2020; 33: 78-85
- OXA-1 beta-lactamase and non-susceptibility to penicillin/beta-lactamase inhibitor combinations among ESBL-producing Escherichia coli.J Antimicrob Chemother. 2019; 74: 326-333
- Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae Bacteremia.Open Forum Infect Dis. 2016; 3: ofw132
- Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo de Estudio de Infeccion Hospitalaria G. beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.Clin Infect Dis. 2012; 54: 167-174
- Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.PLoS One. 2016; 11: e0153696
- Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia.Clin Infect Dis. 2015; 60: 1319-1325
- Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis.Diagn Microbiol Infect Dis. 2014; 80: 222-226
- Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam.Turk J Med Sci. 2016; 46: 1760-1764
- Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.BMC Infect Dis. 2017; 17: 404
- Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli.Int J Antimicrob Agents. 2017; 49: 410-415
- Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by ESBL-producing Organisms?.Clin Infect Dis. 2019; 71: e331-e337
- Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy.BMC Res Notes. 2019; 12: 611
- Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to 2016.Antimicrob Resist Infect Control. 2019; 8: 144
- Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.Eur J Clin Microbiol Infect Dis. 2018; 37: 305-311
- Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward.Eur J Intern Med. 2018; 48: 50-56
- Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.Infect Control Hosp Epidemiol. 2015; 36: 981-985
- PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN).(Available at:) (Accessed 16 September 2021)
- Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.Antimicrob Agents Chemother. 2012; 56: 3936-3942
- Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.Antimicrob Agents Chemother. 2003; 47: 3442-3447
- In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.Diagn Microbiol Infect Dis. 2004; 49: 41-46
- Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing enterobacteriaceae.Int J Antimicrob Agents. 2018; 51: 155-158
- Clinical spectrum of urine cultures positive for ESBL-producing Escherichia coli in hospitalized patients and impact on antibiotic use.Med Mal Infect. 2014; 44: 530-534
- Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.JAMA Intern Med. 2019; 179: 316-323
- Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. beta-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis.Open Forum Infect Dis. 2019; 6: ofz364
- GlaxoSmithKline. AUGMENTIN® (amoxicillin/clavulanate potassium): Powder for Oral Suspension and Chewable Tablets [Package Insert].(Available at:) (Accessed 14 September 2021)
Centers for Disease Control and Prevention. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE): November 2015 Update - CRE Toolkit, 2015. Available at: https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf.
- Detection and Characterization of Targeted Carbapenem-Resistant Healthcare-Associated Threats: Findings from The Antibiotic Resistance Laboratory Network, 2017 to 2019.Antimicrob Agents Chemother. 2021; 65: e0110521
- Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study.Lancet Infect Dis. 2020; 20: 731-741
- High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-beta-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.Clin Infect Dis. 2016; 63: 954-958
- Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016.Diagn Microbiol Infect Dis. 2019; 93: 250-257
- Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates.J Clin Microbiol. 2018; 56: e01140-18
- In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17).J Antimicrob Chemother. 2020; 75: 384-391
- Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates.J Antimicrob Chemother. 2021; 76: 3125-3134
- Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018.Antimicrob Agents Chemother. 2020; 64: e01951-19
- In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.Int J Antimicrob Agents. 2018; 52: 144-150
- Defining the Role of Novel beta-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.J Pediatr Infect Dis Soc. 2019; 8: 251-260
- Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.Clin Infect Dis. 2013; 57: 524-531
- Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.Eur J Clin Microbiol Infect Dis. 2017; 36: 2319-2327
- First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.Antimicrob Agents Chemother. 2015; 59: 6605-6607
- Searching for the Optimal Treatment for Metallo- and Serine-beta-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam.Antimicrob Agents Chemother. 2019; 63: e01426-19
- Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam.J Antimicrob Chemother. 2020; 75: 773-775
- Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases.Int J Antimicrob Agents. 2020; 55: 105842
- Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-beta-lactamase-Producing Enterobacterales.Clin Infect Dis. 2021; 72: 1871-1878
- Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model.J Antimicrob Chemother. 2020; 75: 2622-2632
- Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.Int J Antimicrob Agents. 2019; 53: 520-524
- Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.J Antimicrob Chemother. 2013; 68: ii25-ii35
- Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens.Medicine (Baltimore). 2018; 97: e12467
- Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.Antimicrob Agents Chemother. 2017; 61: e00883-17
- Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.Clin Infect Dis. 2018; 66: 163-171
- Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.Infect Dis Ther. 2018; 7: 439-455
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.Clin Infect Dis. 2020; 70: 1799-1808
- Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study.J Antimicrob Chemother. 2021; 76: 775-783
- Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia.Int J Infect Dis. 2021; 109: 1-7
- Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients.Int J Infect Dis. 2017; 59: 118-123
- Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.BMC Infect Dis. 2019; 19: 772
- Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.Clin Infect Dis. 2019; 68: 355-364
- Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.Antimicrob Agents Chemother. 2017; 61: e02097-16
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.Clin Infect Dis. 2016; 63: 1615-1618
- Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections.Clin Infect Dis. 2019; 71: 667-671
- Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime.Clin Infect Dis. 2020; 71: 2713-2716
- Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.Antimicrob Agents Chemother. 2018; 62: e02497-17
- Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa.Open Forum Infect Dis. 2021; 8: ofab371
- Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents.Clin Infect Dis. 2018; 67: 1803-1814
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.Clin Microbiol Infect. 2012; 18: 268-281
- Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.Clin Microbiol Rev. 2009; 22: 582-610
- Mechanisms of beta-lactam resistance among Pseudomonas aeruginosa.Curr Pharm Des. 2013; 19: 209-222
- In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.Antimicrob Agents Chemother. 2017; 61: e00472-17
- In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.Antimicrob Agents Chemother. 2018; 62: e02569-17
- Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.Antimicrob Agents Chemother. 2016; 60: 3227-3231
- Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.Antimicrob Agents Chemother. 2020; 64: e01955-19
- Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.J Antimicrob Chemother. 2017; 72: 1704-1708
- In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.Diagn Microbiol Infect Dis. 2020; 97: 115012
- In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.Antimicrob Agents Chemother. 2018; 62: e01968-17
- In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.Int J Antimicrob Agents. 2019; 53: 456-466
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.Lancet Infect Dis. 2021; 21: 226-240
- Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.Clin Infect Dis. 2020; 71: 304-310
- Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.J Antimicrob Chemother. 2018; 73: 2519-2523
- Accurate identification of clinically important Acinetobacter spp.: an update.Future Sci OA. 2019; 5: FSO395
- Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.Clin Infect Dis. 2006; 43: S49-S56
- Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.Antimicrob Agents Chemother. 2015; 59: 1680-1689
- Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel beta-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii.Antimicrob Agents Chemother. 2018; 62: e01576-17
- TEM-1 beta-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii.J Antimicrob Chemother. 2013; 68: 2786-2791
- Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis.J Glob Antimicrob Resist. 2021; 24: 136-147
- Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.Crit Care. 2017; 21: 319
- Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia.J Infect Dev Ctries. 2015; 9: 476-485
- Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.Lancet Infect Dis. 2018; 18: 391-400
- Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.Antimicrob Agents Chemother. 2014; 58: 5598-5601
- Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.Clin Infect Dis. 2013; 57: 349-358
- Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.Epidemiol Infect. 2013; 141: 1214-1222
- Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial.J Glob Antimicrob Resist. 2019; 17: 66-71
- Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study.Indian J Crit Care Med. 2018; 22: 67-77
- Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.Clin Microbiol Rev. 2012; 25: 2-41
- Stenotrophomonas maltophilia - a low-grade pathogen with numerous virulence factors.Infect Dis (Lond). 2019; 51: 168-178
- Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.Antimicrob Agents Chemother. 2007; 51: 359-360
- Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia.J Antimicrob Chemother. 2010; 65: 483-489
- Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for Stenotrophomonas maltophilia.Antimicrob Agents Chemother. 2021; 65: e02631-20
- Evaluation of the Vitek 2, Phoenix and Microscan for Antimicrobial Susceptibility Testing of Stenotrophomonas maltophilia.J Clin Microbiol. 2021; 59: e0065421
- Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.PLoS One. 2016; 11: e0152132
- Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem.Ann Clin Microbiol Antimicrob. 2006; 5: 23
- Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?.Antimicrob Agents Chemother. 2014; 58: 581-583
- Clinical factors associated with acquisition of resistance to levofloxacin in Stenotrophomonas maltophilia.Yonsei Med J. 2014; 55: 987-993
- A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.Infect Dis (Lond). 2015; 47: 846-851
- Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.PLoS One. 2016; 11: e0156690
- Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.Antimicrob Agents Chemother. 2004; 48: 946-953
- Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections.Antimicrob Agents Chemother. 2019; 63: e00788-19
- Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates.J Antimicrob Chemother. 2000; 45: 115-117
- Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.J Clin Microbiol. 2020; 58: e01603-19
- Stenotrophomonas maltophilia: an emerging opportunist human pathogen.Lancet Infect Dis. 2009; 9: 312-323
- Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections.Antimicrob Agents Chemother. 2010; 54: 2735-2737
- In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole.Antimicrob Agents Chemother. 2002; 46: 3997-3999
- Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.Antimicrob Agents Chemother. 2020; 64: e00559-20
- In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.J Antimicrob Chemother. 2019; 74: 380-386
- In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.Clin Infect Dis. 2019; 69: S544-S551
- Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model.Antimicrob Agents Chemother. 2019; 63: e01558-19
- Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.Antimicrob Agents Chemother. 2020; 64: e00297-20
- Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.Antimicrob Agents Chemother. 2017; 61: e00777-17
- Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.J Antimicrob Chemother. 2016; 71: 1071-1075
- Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.BMC Microbiol. 2021; 21: 60
- Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.Antimicrob Agents Chemother. 2020; 64: e01433-20
- Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-beta-Lactamase-Producing Gram-Negative Bacteria.Antimicrob Agents Chemother. 2019; 63: e00010-19
- Successful Treatment of Bloodstream Infection Due to Metallo-beta-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient.Antimicrob Agents Chemother. 2016; 60: 5130-5134
- Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes.Clin Infect Dis. 1996; 22: 508-512
- Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals.Open Forum Infect Dis. 2022; 9: ofab644
- Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections.J Antimicrob Chemother. 2016; 71: 3620
- Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.PLoS One. 2016; 11: e0156690
Article info
Identification
Copyright
Published by Elsevier Inc.
